These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20981524)

  • 61. Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.
    Talamas FX; Abbot SC; Anand S; Brameld KA; Carter DS; Chen J; Davis D; de Vicente J; Fung AD; Gong L; Harris SF; Inbar P; Labadie SS; Lee EK; Lemoine R; Le Pogam S; Leveque V; Li J; McIntosh J; Nájera I; Park J; Railkar A; Rajyaguru S; Sangi M; Schoenfeld RC; Staben LR; Tan Y; Taygerly JP; Villaseñor AG; Weller PE
    J Med Chem; 2014 Mar; 57(5):1914-31. PubMed ID: 24195700
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
    Chen YL; Tang J; Kesler MJ; Sham YY; Vince R; Geraghty RJ; Wang Z
    Bioorg Med Chem; 2012 Jan; 20(1):467-79. PubMed ID: 22100256
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.
    LaPlante SR; Padyana AK; Abeywardane A; Bonneau P; Cartier M; Coulombe R; Jakalian A; Wildeson-Jones J; Li X; Liang S; McKercher G; White P; Zhang Q; Taylor SJ
    J Med Chem; 2014 Mar; 57(5):2074-90. PubMed ID: 24467709
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular design and synthesis of HCV inhibitors based on thiazolone scaffold.
    Al-Ansary GH; Ismail MA; Abou El Ella DA; Eid S; Abouzid KA
    Eur J Med Chem; 2013 Oct; 68():19-32. PubMed ID: 23933047
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors.
    Chen HJ; Wang WL; Wang GF; Shi LP; Gu M; Ren YD; Hou LF; He PL; Zhu FH; Zhong XG; Tang W; Zuo JP; Nan FJ
    ChemMedChem; 2008 Sep; 3(9):1316-21. PubMed ID: 18663717
    [No Abstract]   [Full Text] [Related]  

  • 66. Author's overview: identifying SARS-CoV-2 antiviral compounds.
    Diffley JFX
    Biochem J; 2021 Jul; 478(13):2533-2535. PubMed ID: 34198320
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery.
    López-Vallejo F; Caulfield T; Martínez-Mayorga K; Giulianotti MA; Nefzi A; Houghten RA; Medina-Franco JL
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):475-87. PubMed ID: 21521151
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase.
    Chan L; Reddy TJ; Proulx M; Das SK; Pereira O; Wang W; Siddiqui A; Yannopoulos CG; Poisson C; Turcotte N; Drouin A; Alaoui-Ismaili MH; Bethell R; Hamel M; L'Heureux L; Bilimoria D; Nguyen-Ba N
    J Med Chem; 2003 Apr; 46(8):1283-5. PubMed ID: 12672227
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase.
    Kumar DV; Rai R; Brameld KA; Riggs J; Somoza JR; Rajagopalan R; Janc JW; Xia YM; Ton TL; Hu H; Lehoux I; Ho JD; Young WB; Hart B; Green MJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):300-4. PubMed ID: 22119470
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 2D and 3D quantitative structure-activity relationship study of hepatitis C virus NS5B polymerase inhibitors by comparative molecular field analysis and comparative molecular similarity indices analysis methods.
    Pourbasheer E; Aalizadeh R; Shokouhi Tabar S; Ganjali MR; Norouzi P; Shadmanesh J
    J Chem Inf Model; 2014 Oct; 54(10):2902-14. PubMed ID: 25181564
    [No Abstract]   [Full Text] [Related]  

  • 71. Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism.
    Leivers M; Miller JF; Chan SA; Lauchli R; Liehr S; Mo W; Ton T; Turner EM; Youngman M; Falls JG; Long S; Mathis A; Walker J
    J Med Chem; 2014 Mar; 57(5):1964-75. PubMed ID: 24224729
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.
    Barreca ML; Iraci N; Manfroni G; Cecchetti V
    Future Med Chem; 2011 Jun; 3(8):1027-55. PubMed ID: 21707403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design, synthesis and biological evaluation of small molecules as potent glucosidase inhibitors.
    Hati S; Madurkar SM; Bathula C; Thulluri C; Agarwal R; Siddiqui FA; Dangi P; Adepally U; Singh A; Singh S; Sen S
    Eur J Med Chem; 2015 Jul; 100():188-96. PubMed ID: 26087029
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Practices in Molecular Docking and Structure-Based Virtual Screening.
    Dos Santos RN; Ferreira LG; Andricopulo AD
    Methods Mol Biol; 2018; 1762():31-50. PubMed ID: 29594766
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.
    Dunsdon RM; Greening JR; Jones PS; Jordan S; Wilson FX
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1577-9. PubMed ID: 10915055
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation.
    Szilágyi B; Skok Ž; Rácz A; Frlan R; Ferenczy GG; Ilaš J; Keserű GM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1693-1698. PubMed ID: 29699925
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rapid discovery of potent α-fucosidase inhibitors by in situ screening of a library of (pyrrolidin-2-yl)triazoles.
    Elías-Rodríguez P; Moreno-Clavijo E; Carmona AT; Moreno-Vargas AJ; Robina I
    Org Biomol Chem; 2014 Aug; 12(31):5898-904. PubMed ID: 24984102
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Zika virus NS5 protein potential inhibitors: an enhanced in silico approach in drug discovery.
    Ramharack P; Soliman MES
    J Biomol Struct Dyn; 2018 Apr; 36(5):1118-1133. PubMed ID: 28351337
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
    Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.